Growth Drivers
•Rising prevalence of neurological autoimmune indications (e.g., CIDP, myasthenia gravis) is expanding the addressable patient pool; FDA-cleared indications have grown 40 % since 2019, directly pulling through new TPE kit sales and underpinning a 9 % CAGR in the Therapeutic Plasma Exchange market size through 2028.
•Shift toward integrated column-based automated systems with 30 % shorter treatment windows is accelerating hospital adoption; capital-equipment leasing models cut upfront cost by 55 %, enabling mid-tier hospitals to add TPE programs and boosting volume forecasts in the growth forecast model.
Restraints
•Supply-chain concentration risk for 1.2 mm centrifuge membrane filters—dominated by two EU suppliers—has created 8–12 week lead times, forcing providers to idle suites and capping 2023 procedure growth at 3 % versus the planned 7 %.
•CMS reimbursement compression (2024 Medicare proposed cut of 12 % for Category III CPT codes) threatens hospital contribution margin, already slim at 18 %; if finalized, capital budgets will pivot away from new TPE installations next year.
Opportunities
•Next-generation immunoadsorption columns that selectively deplete IgG while returning native plasma are entering Phase III; early data show 35 % higher remission rates versus standard TPE, creating a premium pricing tier that could lift average selling prices 22 % and widen the Therapeutic Plasma Exchange market.
•Ambulatory surgery center (ASC) migration is gaining payer support—three commercial insurers added TPE coverage in 2023; ASC settings cut facility cost 28 %, opening a site-of-care shift projected to add US$180 mn to the U.S. market by 2027.
Challenges
•Biologics pipeline (e.g., FcRn inhibitors) offers once-weekly subcutaneous alternatives; if two late-stage assets gain approval 2025–2026, our epidemiology model indicates a potential 15 % erosion in chronic TPE volumes within two years of launch.
•Talent scarcity of certified apheresis nurses (vacancy rate 14 % nationally) is elongating treatment queues; without workforce intervention, average wait times >6 weeks risk patient leakage to competing immunotherapies and suppress real-world procedure growth below base-case forecasts.
